Applied Molecular Transport

Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood on November 21, 2016 and is headquartered in Menlo Park, CA.

Company continues to strengthen key functions of corporate leadership

Applied Molecular Transport Appoints Earl Douglas as General Counsel

Successfully initiated four planned Phase 2 trials for oral AMT-101 with enrollment ongoing

Applied Molecular Transport Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Gritstone Oncology Inc

Moderna

Here's why these highfliers could have more fuel in the tank.

3 Biotech Stocks That Have Already Rocketed Higher in 2021

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 11:20 a.m. ET.

Applied Molecular Transport to Present at Oppenheimer 31st Annual Healthcare Conference

Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126

News for Applied Molecular Transport Stock (AMTI)